| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 17852 |
| Title of Study | RIFTOS - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors |
| Primary Objective | The primary objective of this study is to compare time to symptomatic progression (TTSP) from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry with that of asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. The two cohorts are defined based on the investigators’ treatment decisions at study entry. The day of study entry is the point when the physician will make the treatment decision/choice just after progression is confirmed. |
| Number of Sites | 5 |
| Period of Study | From：08/2015 to：03/2019 |
| Number of Patients | 43人 |
| IRB Approval Date | VGHTPE: May/12/2015 |
| Publication Plan / Date | 03/2020 |
